News & Updates

A screen-and-prevent strategy for preterm preeclampsia (PE), which involves screening in the first trimester and low-dose aspirin prophylaxis for high-risk women in <16–36 weeks of gestation, will be launched in obstetric units of public hospitals across Hong Kong following promising results from a multicentre Asian trial led by the Chinese University of Hong Kong (CUHK) and a pilot programme at the Prince of Wales Hospital (PWH).

Patients with high-risk locally advanced cervical cancer in East Asia get progression-free survival (PFS) boost with pembrolizumab plus concurrent chemoradiotherapy (CCRT), similar to those observed in the overall population of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.

Treatment with carboplatin-paclitaxel (CP) plus atezolizumab results in better quality-adjusted survival in patients with advanced or recurrent endometrial cancer (EC) as compared with CP alone, according to a post hoc analysis of the AtTEnd/ENGOT-EN7 trial.